BIOQUAL Presents Financial Results for Third Quarter of Fiscal Year 2018

ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL, Inc. (OTC Pink: BIOQ) (www.bioqual.com):

  Nine Months Ended     Three Months Ended
February 28,     February 28, February 28,     February 28,
2018 2017 2018 2017
Revenue $ 26,132,351 $ 27,716,798 $ 8,331,395 $ 9,068,275
Income Before Income Tax $ 3,824,580 $ 4,949,235 1,202,918 1,459,486
Net Income $ 2,312,980 $ 2,858,135 799,018 842,786
 

Basic Earnings per Share of Common Stock

$

2.59

$

3.20

.89

.94

 

Diluted Earnings per Share of Common Stock

$

2.59

$

3.20

.89

.94

 

Weighted Average Number of Shares Outstanding For Basic Earnings

 

 

893,932

 

893,416

 

894,416

893,416

Weighted Average Number of Shares Outstanding For Diluted Earnings

 

893,932

 

893,416

 

894,416

 

893,416

Subsequent Development

In April 2018, the Company subscribed to the OTC Disclosure and News
Service and now discloses quarterly and annual financial and other
corporate information to the OTC Pink Marketplace. The information
disclosure meets the OTC requirements necessary to reclassify BIOQUAL’s
listing from the “No Information” category to the “Current Information”
category. Although the Company will continue its historic practice of
disclosing its financial results on its website, the information
reported to the OTC will provide additional information required by the
OTC. The annual subscription cost for this service is $5,000.

For more detail related to the fiscal year 2018 third quarter results,
please visit our web site at www.bioqual.com
and OTCMarkets.com/stock/BIOQ/disclosure.

Statements herein that are not descriptions of historical facts are
forward-looking and subject to risk and uncertainties. Actual results
could differ materially from those currently anticipated due to a number
of factors including risks relating to the ability to continue to extend
current government contracts and obtain new contracts; the Company’s
ability to obtain new commercial contracts; the performance of the
business acquired in the ABL acquisition; the Company’s ability to
perform under its contracts in accordance with the requirements of the
contracts; the actual cost incurred in performing its contracts and the
Company’s ability to manage its costs; dependence on third parties;
future capital needs; the ability to fund its capital needs through the
use of its cash on hand and line of credit; and the future availability
and cost of financing/capital sources to the Company.

Contacts

BIOQUAL, Inc.
Mark G. Lewis, Ph.D., CEO, 240-404-7654